Patient and GVHD characteristics, diagnosis cohort
| . | cGVHD cohort (n = 211) . | ||
|---|---|---|---|
| cGVHD (n = 178) . | Controls (n = 33) . | P . | |
| Age, y | |||
| Median | 52 | 54 | .55 |
| Range | 19-79 | 22-72 | |
| Sex, n (%) | |||
| Female | 77 (43) | 18 (55) | .23 |
| Male | 101 (57) | 15 (45) | |
| Donor type and match, n (%) | |||
| Matched sibling | 66 (37) | 18 (55) | .06 |
| Other* | 112 (63) | 15 (45) | |
| Stem cell source, n (%) | |||
| PBSC | 161 (90) | 26 (79) | .05 |
| Other | 17 (10) | 7 (21) | |
| Conditioning regimen intensity, n (%) | |||
| Myeloablative | 105 (59) | 19 (58) | .88 |
| Nonmyeloablative | 73 (41) | 14 (42) | |
| Prior acute GVHD, n (%)† | |||
| Yes | 135 (76) | 24 (73) | .70 |
| No | 43 (34) | 9 (37) | |
| Time post-HCT to cGVHD diagnosis, d | |||
| Median | 210 | NA | NA |
| Range | 38-1757 | NA | |
| Time post-HCT to sample acquisition, d | |||
| Median | 391 | 369 | .84 |
| Range | 192-1852 | 161-3641 | |
| NIH global severity, n (%)† | |||
| Mild | 13 (7) | NA | NA |
| Moderate | 103 (58) | NA | |
| Severe | 62 (35) | NA | |
| . | cGVHD cohort (n = 211) . | ||
|---|---|---|---|
| cGVHD (n = 178) . | Controls (n = 33) . | P . | |
| Age, y | |||
| Median | 52 | 54 | .55 |
| Range | 19-79 | 22-72 | |
| Sex, n (%) | |||
| Female | 77 (43) | 18 (55) | .23 |
| Male | 101 (57) | 15 (45) | |
| Donor type and match, n (%) | |||
| Matched sibling | 66 (37) | 18 (55) | .06 |
| Other* | 112 (63) | 15 (45) | |
| Stem cell source, n (%) | |||
| PBSC | 161 (90) | 26 (79) | .05 |
| Other | 17 (10) | 7 (21) | |
| Conditioning regimen intensity, n (%) | |||
| Myeloablative | 105 (59) | 19 (58) | .88 |
| Nonmyeloablative | 73 (41) | 14 (42) | |
| Prior acute GVHD, n (%)† | |||
| Yes | 135 (76) | 24 (73) | .70 |
| No | 43 (34) | 9 (37) | |
| Time post-HCT to cGVHD diagnosis, d | |||
| Median | 210 | NA | NA |
| Range | 38-1757 | NA | |
| Time post-HCT to sample acquisition, d | |||
| Median | 391 | 369 | .84 |
| Range | 192-1852 | 161-3641 | |
| NIH global severity, n (%)† | |||
| Mild | 13 (7) | NA | NA |
| Moderate | 103 (58) | NA | |
| Severe | 62 (35) | NA | |